Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines.
The last earnings update was 48 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Syros Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Syros Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Syros Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Syros Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Syros Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Syros Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Syros Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Syros Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Syros Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 3281.7x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Nancy A. Simonian, M.D., has been the Chief Executive Officer and President at Syros Pharmaceuticals, Inc. since July 2012. Dr. Simonian has served as a Director of Evelo Biosciences, Inc. Since April 2018. Dr. Simonian served as the Principal Financial Officer of Syros Pharmaceuticals, Inc. since September 28, 2017 until December 06, 2017. She served as the Chief Medical Officer of Clinical, Medical & Regulatory Affairs at Millennium Pharmaceuticals, Inc. She served as the Chief Medical Officer of Millennium Pharmaceuticals Inc. since 2006. While at Millennium, Dr. Simonian has built a strong clinical development organization which effectively executes on a diverse pipeline of product candidates in Millennium Pharmaceuticals Inc.'s oncology, inflammatory disease and cardiovascular disease focus areas. She served as Senior Vice President, Clinical, Regulatory and Medical Affairs of Millennium Pharmaceuticals Inc. from March 14, 2005 to 2006. She was responsible for guiding the clinical development process for the approval of VELCADE. In her expanded role, Dr. Simonian leads an integrated medical organization which consolidates all medical functions, including clinical development, regulatory affairs, pharmacovigilance and global medical affairs. She joined Millennium Pharmaceuticals in 2001. She co-leads Millennium Pharmaceuticals Inc.’s pipeline portfolio review committee and direct a streamlined clinical drug development process through post-approval life- cycle. Dr. Simonian served at Biogen, Inc. from 1995 to 2001 and also held the positions of Vice President of Medical Research/clinical research. At Biogen, she was responsible for the oversight of Avonex Tysabri, as well as multiple gene therapy clinical development programs. She successfully filed sNDAS for Avonex and led the in-licensing of Tysabri from Elan Pharmaceuticals. She has been a Director of Seattle Genetics, Inc. since March 2012 and Syros Pharmaceuticals, Inc since April 2013. Dr. Simonian served as a Director of Arqule Inc. from May 12, 2006 to March 31, 2011. Dr. Simonian is Assistant Clinical Professor, Neurology, at Harvard Medical School/Massachusetts General Hospital. Dr. Simonian holds a BA in Biology from Princeton University in 1983 and an M.D. from the University Of Pennsylvania Medical School in 1988. Dr. Simonian completed her internship in Medicine and residency in Neurology at Harvard Medical School/Massachusetts General Hospital.
Nancy's compensation has increased whilst company is loss making.
Nancy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Syros Pharmaceuticals management team is about average.
Chief Medical Officer
Chief Business Officer
Scientific Founder & Member of Scientific Advisory Board
Chief Financial Officer
Chief Scientific Officer
Chief Legal & Administrative Officer and Secretary
Vice President of Corporate Communications & Investor Relations
Head of Biology
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Syros Pharmaceuticals board of directors is about average.
Board of Directors
Scientific Founder & Member of Scientific Advisory Board
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.